Drug Trial Radar · NCT07578337
A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.
Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 15, 2026
Primary completion
Feb 28, 2029
Study completion Feb 28, 2029
Sponsor
- Lead sponsor
- Nelum CorpIndustry
- Sponsor type
- Industry
- Collaborators
- Apices Soluciones S.L.; PH Research, S.L.
- First posted
- May 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II, open label, randomized multicenter study to evaluate efficacy and safety of study treatment in previously untreated patients with advanced pancreatic cancer. Patients will receive study treatment for a maximum of 24 months or until progression disease or until unacceptable toxicity. In the experimental arm, patients who discontinue chemotherapy for reasons other than disease progression may continue receiving the remaining study drugs (NLM-001, botensilimab and balstilimab) up to a maximum of 24 months, according to schedule.
Conditions
- Untreated
- Advanced Pancreatic Cancer
Interventions
Gemcitabine (1000 mg/m2)Drug
Gemcitabine 1,000 mg / m2 IV administered on days 1, 8 and 15 in cycles of 28 days.
Nab-paclitaxel (Abraxane)Drug
Nab-P 125 mg / m2 IV administered on days 1, 8 and 15 in cycles of 28 days.
NLM-001Drug
NLM-001: 800 mg/day, p.o, once daily (4 tablets of 200 mg) days -4 to -1 and 10-13 of each cycle.
BotensilimabDrug
Botensilimab: 75 mg every 6 weeks for 4 administrations, from D1C1.
BalstililmabDrug
Balstilimab: 240 mg IV Day 1 and Day 15 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the response rate in each of the study arms, assessed according to iRECIST criteria, including the confirmation of progression to distinguish true progression from potential pseudoprogression.Time frame: 12 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitario Miguel Servet
Zaragoza, Aragon, Spain
Hospital Clínic Barcelona
Barcelona, Barcelona, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Hospital Universitario de Donostia
San Sebastián, Gipuzkoa, Spain
Complexo Hospitalario Universitario de Santiago
Santiago de Compostela, La Coruña, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Málaga, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.